Wolverine StackTissue repair research blendBlendSafety Rating 8/10

View full research →

Price Comparison

Compare vendors

No vendor pricing available for this peptide yet.

Research details

Wolverine Stack — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeSold as a blend or dosed as two peptides. The schedule is asymmetric, reflecting the components: BPC-157 ~250-500 mcg daily or twice daily (short half-life) plus TB-500 ~2-2.5 mg twice weekly (longer-acting). Calculate each against its own range; many users dose the two peptides separately.
AdministrationSubcutaneous injection
Safety8/10 · Not FDA-approved (blend)
NCAA D1Unclear

Overview

About Wolverine Stack

Mechanism of action

Two-peptide combination of BPC-157 and TB-500 (the thymosin beta-4 fragment) for tissue repair. BPC-157 upregulates actin and growth-factor expression and modulates nitric oxide (angiogenesis, anti-inflammatory); TB-500 sequesters actin to drive cell migration and reduce scarring. The rationale is mechanistic synergy, not combination trial data.

Safety profile

Injection-site reactions; the key safety point is the cancer / active-malignancy contraindication (both peptides are pro-angiogenic) - monitor for unusual tissue growth. WADA-banned. Limited human safety data. Research-use only; not for human consumption. · Marketed BPC-157 + TB-500 'healing stack'; well-tolerated components, but no trial of the combination itself. Both peptides are pro-angiogenic — contraindicated with any cancer history; monitor for unusual tissue growth. WADA-banned.

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cstable long-term
💉Reconstituted2–8°Cwithin 14–30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Blend

Component Compounds

BPC-157

AAs15MW1,419.5 g/mol
GEPPPGKPADDAGLV

VEGFR2/Angiogenesis — origin: Human gastric juice

TB-500

AAs43MW4,963 Da

Actin binding (¹⁷LKKTET²²) / Cell migration — origin: Thymus, platelets

Related pages

More on Wolverine Stack

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Wolverine is a two-peptide COMBINATION (BPC-157 + TB-500), not a single compound — marketed for tissue repair/recovery. Its evidence is the individual components' evidence; there are no trials of the actual combination.
  • BPC-157 (repair/angiogenesis) and TB-500 (cell migration/anti-scarring) act through complementary actin-related pathways — the rationale is mechanistic synergy, not combination data.

4 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch